Research
Hormonal
Obstructive Sleep Apnea (OSA) contributes to obesity through mechanisms including increased preference for calorie-dense foods, altered hormonal regulation (leptin resistance), and decreased physical activity due to daytime sleepiness.
If you have OSA, recognize that your sleep disorder may be driving your weight gain through hormonal changes and fatigue. Treating OSA (e.g., with CPAP) and exercising can help break the cycle of weight gain and improve sleep quality.
GoodSupportsHIGH confidence
OSA impacts energy expenditure and caloric intake and thus overall body weight in a variety of ways, including: (1) changes in energy expenditure during times of sleep and wakefulness; (2) increased preference for energy dense food and increased caloric intake; (3) alteration in hormonal regulation specific to appetite and satiety; and (4) changes in sleep duration, which may decrease physical activity that is attributable to lethargy and daytime sleepiness.
Why this rating
Supported by multiple studies showing the bidirectional relationship and specific mechanisms.
Source
Association between sleep disorders, obesity, and exercise: a review
Trent A. Hargens et al. · Nature and Science of Sleep · 2013
DOI 10.2147/nss.s34838
narrative_reviewCited 240×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Short sleep duration (e.g., 5 hours vs 8 hours) causes hormonal shifts (lower leptin, higher ghrelin) and elevated cortisol that increase appetite and abdominal fat deposition, thereby promoting obesity.Good
- Regular moderate-intensity aerobic exercise improves sleep quality, reduces sleep onset latency, and decreases OSA severity, independent of significant weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →